TY - JOUR
T1 - Pharmacotherapy for tobacco cessation
T2 - Nicotine agonists, antagonists, and partial agonists
AU - Karam-Hage, Maher
AU - Cinciripini, Paul M.
N1 - Funding Information:
discloses that he has received research funding from Sanofi-Aventis and GlaxoSmithKline.
PY - 2007/11
Y1 - 2007/11
N2 - Nicotine replacement therapies (NRT) were the main pharmacologic option for treatment of nicotine dependence until the early 1990s, when controlled clinical trials confirmed the efficacy of bupropion, the first treatment not based on nicotine. Varenicline, a partial agonist at nicotine receptors, gained US regulatory approval in 2006 for smoking cessation. Although these agents are all effective for nicotine dependence, their efficacy rates vary compared with placebo (overall OR for NRT efficacy, 1.77; for bupropion, 1.94; for varenicline, 3.09). Each of these treatments has a place, sometimes in combinations with other agents, in cancer patients who continue to smoke. Our initial experience with varenicline has been encouraging. Bupropion has specific advantages for cancer patients, including increased energy, low risk for nausea, and decreased weight gain from quitting.
AB - Nicotine replacement therapies (NRT) were the main pharmacologic option for treatment of nicotine dependence until the early 1990s, when controlled clinical trials confirmed the efficacy of bupropion, the first treatment not based on nicotine. Varenicline, a partial agonist at nicotine receptors, gained US regulatory approval in 2006 for smoking cessation. Although these agents are all effective for nicotine dependence, their efficacy rates vary compared with placebo (overall OR for NRT efficacy, 1.77; for bupropion, 1.94; for varenicline, 3.09). Each of these treatments has a place, sometimes in combinations with other agents, in cancer patients who continue to smoke. Our initial experience with varenicline has been encouraging. Bupropion has specific advantages for cancer patients, including increased energy, low risk for nausea, and decreased weight gain from quitting.
UR - http://www.scopus.com/inward/record.url?scp=36049009967&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=36049009967&partnerID=8YFLogxK
U2 - 10.1007/s11912-007-0072-6
DO - 10.1007/s11912-007-0072-6
M3 - Review article
C2 - 17991361
AN - SCOPUS:36049009967
SN - 1523-3790
VL - 9
SP - 509
EP - 516
JO - Current oncology reports
JF - Current oncology reports
IS - 6
ER -